eli lilly tirzepatide trial Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head showing an average weight loss of 20.2% vs. 13.7% Endoscopic Procedure Shows Promise for

However, uncertainties persist regarding the prospects for adverse liver effects that might be inherent to the mechanism of action, as stabilisation of hepatic steatosis would be unwelcome

Future multi-receptor therapeutics may need individualized strategies tailored to individual receptor expression profiles or metabolic characteristics

Goldstone AP, Thomas EL, Brynes AE, Castroman G, Edwards R, Ghatei MA, et al

Managing weight often feels like a negotiation with your own biology, one where the rules change as soon as you make progress

I've been concerned about muscle loss on semaglutide - this sounds promising.

HSA and FSA accounts are accepted, allowing you to pay with pre-tax healthcare dollars